In This Section


Please Note: All session times for the AACR Virtual Special Conference: Brain Cancer are U.S. Eastern Time (ET).

Monday, October 25, 2021

Opening Keynote Lectures
Plenary Session 1: Epigenetics and Epitranscriptomics
Plenary Session 2: Novel Therapeutics

tuesday, october 26, 2021

Plenary Session 3: Metabolism and the Tumor Microenvironment
Drug Design for Better CNS Penetration Panel
Closing Keynote Lecture

Monday, October 25, 2021

10-11:15 a.m.

Cohesin-mediated chromosome folding
Job Dekker, University of Massachusetts Medical School, Worcester, Massachusetts

Single cell epigenomics
Bing Ren, University of Southern California San Diego, San Diego, California

11:15-11:30 a.m.
Plenary Session 1: Epigenetics and Epitranscriptomics
11:30-1:00 p.m.

RNA methylation in human cancer
Chaun He, The University of Chicago/ Howard Hughes Medical Institute, Chicago, Illinois

Deconvolution of chromatin programs of stemness at single cell resolution            
Marco Gallo, University of Calgary Cumming School of Medicine, Calgary, Canada

Dissecting glioblastoma by single cell RNA-seq
Itay Tirosh, Weizmann Institute of Science, Rehovot, Israel

Panel Discussion
12:30-1 p.m
1-1:15 p.m.
Plenary Session 2: Novel Therapeutics
1:15-2:15 p.m.

Immunocytokines to treat glioblastoma
Michael Weller, University Hospital Zurich, Switzerland

Integrated development of a brain-penetrant EGFR inhibitor and non-invasive predictive biomarker of response for glioblastoma
David A. Nathanson, University of California Los Angeles, Los Angeles, California

Advancing CAR T cell therapy for glioblastoma
Christine E. Brown, City of Hope National Medical Center, Duarte, California

Panel discussion
2:15-2:45 p.m.


Plenary Session 3: Metabolism and the Tumor Microenvironment
10-11 a.m.

Consistent metabolic adaptations in stressful tumor microenvironments
Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

Exploring and therapeutically exploiting the tumor microenvironment in brain cancers
Johanna A. Joyce, UNIL University of Lausanne, Lausanne, Switzerland

Targeting the PI 3-Kinase pathway in brain cancers
Lewis C. Cantley, Weill Cornell Medicine, New York, New York

panel discussion
11-11:30 a.m.
11:30 A.M-12 P.M.
Drug Design for Better CNS Penetration Panel
Not eligible for CME credit
12-1:30 P.M.

Aberrant DNA repair as a therapeutic target in glioblastoma
Petra Hamerlik, Danish Cancer Society Research Center, Copenhagen, Denmark

Advances in the biology and treatment of pediatric CNS tumors
Mark W. Kieran, Day One Biopharmaceutical, Yardley, Pennsylvania

1:30-1:45 p.m.
CLOSING KEYNOTE and closing remarks
1:45-2:30 p.m.

Precision immunotherapy targeting malignant brain tumors
Duane A. Mitchell, University of Florida, Gainesville, Florida